Siemens Medical Systems has received 510(k) marketing clearancefor an upgrade package for its Magnetom Open MRI scanner thatenables clinicians to perform MRI-guided procedures with the scanner.The FDA's move also allows the Iselin, NJ, vendor to promote
Siemens Medical Systems has received 510(k) marketing clearancefor an upgrade package for its Magnetom Open MRI scanner thatenables clinicians to perform MRI-guided procedures with the scanner.The FDA's move also allows the Iselin, NJ, vendor to promote theuse of Open for interventional imaging, which was not includedin Open's original 510(k) clearance document (SCAN 4/6/94).
Siemens' MR-Guided Procedures Package includes hardware suchas a bore light, ergonomic chair, foot pedal to initiate scans,multipurpose 35-cm coil, auto-display of images as they are acquired,and an optional in-room monitor. It also includes fast imagingsequences, according to Anne Deery Sheehan, Open product manager.
The package was designed to allow clinicians to conduct MR-guidedbiopsies and drainages on a range of anatomyfrom the head andneck to the spine, abdomen, and extremities. The package has beenunder evaluation at University Hospitals of Cleveland and at sevensites in Europe.
Siemens believes that the option is the first clinically availableMR-guided surgery package. Siemens will offer the package as anoption for installed Open scanners, with a list price of $155,000including in-room monitor. A new Open with the package will probablylist for around $1 million.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.